Related Experiment Video
Updated: Dec 13, 2025
05:45
Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality
Published on: April 7, 2023
4.1K
A Regulatory Perspective on Manufacturing Processes Pertaining to Lyophilized Injectable Products
Steve Y Rhieu1, David D Anderson2, Kumar Janoria2
1Office of Pharmaceutical Manufacturing Assessment, Office of Pharmaceutical Quality, Center of Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, 20993, USA. steve.rhieu@fda.hhs.gov.
The AAPS Journal
|August 4, 2020
Summary
This report details regulatory considerations for manufacturing lyophilized (freeze-dried) injectable drugs. It aims to help the pharmaceutical industry avoid common deficiencies in regulatory submissions for these critical products.
Area of Science:
- Pharmaceutical Manufacturing
- Drug Product Stability
- Regulatory Science
Background:
- Lyophilization, or freeze-drying, is crucial for extending the shelf life of injectable drug products.
- Ensuring product quality and regulatory compliance in lyophilized drug manufacturing is essential for patient safety.
- The pharmaceutical industry requires clear guidance on regulatory expectations for lyophilized injectable product processes.
Purpose of the Study:
- To provide regulatory considerations for key unit operations in lyophilized injectable product manufacturing.
- To identify common manufacturing-related deficiencies in regulatory submissions for lyophilized injectables.
- To assist the pharmaceutical industry in establishing robust and compliant manufacturing processes.
Main Methods:
- Review of regulatory considerations for compounding, filtration, filling, and lyophilization unit operations.
- Analysis of manufacturing-related deficiencies from 263 New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
- Compilation of insights to guide pharmaceutical manufacturers in regulatory submissions.
Main Results:
- Identification of specific regulatory challenges and deficiencies across various manufacturing stages.
- A comprehensive list of common manufacturing-related deficiencies encountered in regulatory submissions.
- Guidance on establishing reliable manufacturing processes from a regulatory standpoint.
Conclusions:
- Adherence to regulatory considerations can help avoid common manufacturing deficiencies.
- Streamlined regulatory submissions facilitate the timely availability of high-quality lyophilized pharmaceuticals.
- This information supports the pharmaceutical industry in meeting regulatory expectations for lyophilized injectables.
Related Concept Videos
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
315
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
315
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
107
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
107
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
124
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
124
01:25Drug Regulation
2.6K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.6K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
149
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
149
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
93
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
93